Urology
Volume 68, Issue 2, Supplement , Pages 17-28 , August 2006

Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures

  • Paul Abrams

      Affiliations

    • Bristol Urological Institute, Southmead General Hospital, Bristol, United Kingdom
    • Paul Abrams is a consultant/advisor for Pfizer Inc, Novartis, Ferring, and Plethora; a meeting participant/lecturer for Pfizer Inc, Novartis, Ferring, and Lilly; and participates in scientific studies/trials for Ferring, Plethora, and Lilly.
    • Corresponding Author InformationReprint requests: Paul Abrams, MD, Bristol Urological Institute, Southmead General Hospital, Westbury-On-Trym, Bristol, BS10 5NB, United Kingdom.
    • ,
  • Walter Artibani

      Affiliations

    • University of Padova, Padova, Italy
    • ,
  • Jerzy B. Gajewski

      Affiliations

    • Department of Urology, Dalhousie University, Halifax, Nova Scotia, Canada
    • Jerzy B. Gajewski is on a National Advisory Board for Pfizer Canada Inc., Eli Lilly Canada Inc., Bayer Inc., Janssen-Ortho, Sanofi-Synthelabo, Canada Inc., Allergan Inc., and Solvay Pharma Inc.; and an investigator for Medtronic, Pfizer Canada Inc., Eli Lilly Canada Inc., Bayer Inc., Janssen-Ortho, and Allergan Inc.
    • ,
  • Iqbal Hussain

      Affiliations

    • Pfizer Inc, New York, New York, USA
    • Iqbal Hussain was employed by Pfizer Inc.

References 

  1. Abrams P , Cardozo L , Fall M , et al.   The standardisation of terminology in lower urinary tract function (report from the standardisation sub-committee of the International Continence Society) . Urology . 2003;61:37–49
  2. Coyne K , Payne C , Bhattacharyya S , et al.   The impact of urinary urgency and frequency on health-related quality of life in overactive bladder (results from a national community survey) . Value Health . 2004;7:451–459
  3. Liberman JN , Hunt TL , Stewart WF , et al.   Health-related quality of life among adults with symptoms of overactive bladder (results from a U.S. community-based survey) . Urology . 2001;57:1044–1050
  4. Rogers R , Margolis MK , Bavendam T , et al.   Overactive bladder with urinary incontinence adversely affects women’s sexual quality of life . 2005; Presented at the XXth Congress of the European Association of Urology; March 16-19, Istanbul, Turkey.
  5. Milsom I , Irwin DE , Kopp Z , et al.   Impact of overactive bladder symptoms on employment, daily life, and emotional well-being among European men and women . 2005; Presented at the XXth Congress of the European Association of Urology; March 16-19, Istanbul, Turkey.
  6. Khullar, V, Chapple C, Gabriel Z, et al: The effects of antimuscarinics on quality of life in overactive bladder: a systematic review and meta-analysis. Urology. In press.
  7. Wiklund I . Assessment of patient-reported outcomes in clinical trials (the example of health-related quality of life) . Fundam Clin Pharmacol . 2004;18:351–363
  8. Fairclough DL . Patient reported outcomes as endpoints in medical research . Stat Methods Med Res . 2004;13:115–138
  9. Coyne KS , Kelleher CJ . Clinical versus patient outcomes (whose outcome has greater value?) . BMJ . 2003; [online; rapid response] Nov
  10. DuBeau CE , Levy B , Mangione CM , et al.   The impact of urge urinary incontinence on quality of life (importance of patients’ perspective and explanatory style) . J Am Geriatr Soc . 1998;46:683–692
  11. Donovan J , Badia X , Corcos J , et al.   Committee 6 (symptom and quality of life assessment) . In:  Abrams P ,  Cardozo L ,  Khoury S , et al. editor. Incontinence . Plymouth, United Kingdom: Plymbridge Distributors, Ltd; 2002;p. 267–316
  12. Marschall-Kehrel D , Roberts RG , Brubaker L . Patient-reported outcomes in overactive bladder (the influence of perception of condition and expectation for treatment benefit) . Urology . 2006;68(suppl 2A):29–37
  13. Coyne KS , Matza LS , Thompson CL . The responsiveness of the Overactive Bladder Questionnaire (OAB-q) . Qual Life Res . 2005;14:849–855
  14. Chapple C , Khullar V , Gabriel Z , et al.   The effects of antimuscarinic treatments in overactive bladder (a systematic review and meta-analysis) . Eur Urol . 2005;48:5–26
  15. Alloussi S , Luval K-U , Eckert R , et al.   Trospium chloride in patients with motor urge syndrome (detrusor instability) (a double-blind, randomized, multicentre, placebo-controlled study) . J Clin Res . 1998;1:439–451
  16. Brambila EAS , Avila RGQ , Monterrubio JLL , et al.   Evaluation of the effectiveness and tolerance of oxybutynin in the treatment of unstable bladder in women . [translated from Spanish] Ginecol Obstet Mex . 2000;68:174–181
  17. Burgio KL , Locher JL , Roth DL , et al.   Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women . J Gerontol B Psychol Sci Soc Sci . 2001;56:P46–P51
  18. Cardozo L , Chapple CR , Toozs-Hobson P , et al.   Efficacy of trospium chloride in patients with detrusor instability (a placebo-controlled, randomized, double-blind, multicentre clinical trial) . BJU Int . 2000;85:659–664
  19. Dmochowski RR , Davila GW , Zinner NR , et al.   Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence . J Urol . 2002;168:580–586
  20. Halaska M , Dorschner W , Frank M . Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride . Neurourol Urodyn . 1994;13:428–430
  21. Jünemann KP , Hessdoerfer E , Unamba-Oparah I , et al.   Propiverine hydrochloride immediate (IR) and extended release (ER) (comparison of efficacy and tolerability in patients with overactive bladder) . 2004; Presented at the 34th Meeting of the International Continence Society; August 23-27, Paris, France. Abstract 143.
  22. Khullar V , Hill S , Laval K-U , et al.   Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release (a randomized, placebo-controlled trial) . Urology . 2004;64:269–275
  23. Millard R , Tuttle J , Moore K , et al.   Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity . J Urol . 1999;161:1551–1555
  24. Moore KH , Hay DM , Imrie AE , et al.   Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability . Br J Urol . 1990;66:479–485
  25. Rentzhog L , Stanton SL , Cardozo L , et al.   Efficacy and safety of tolterodine in patients with detrusor instability (a dose-ranging study) . Br J Urol . 1998;81:42–48
  26. Rudy D , Cline K , Goldberg K , et al.   A multicenter randomised, placebo-controlled trial of trospium chloride in overactive bladder patients . 2004; Presented at the 34th Meeting of the International Continence Society; August 23-27, Paris, France. Abstract 144.
  27. Steers W , Corcos J . Efficacy, tolerability, and safety of darifenacin, an M3 selective antagonist for the treatment of overactive bladder, using a flexible dosing regimen . Prog Urol . 2004;14(suppl 3):68
  28. Szonyi G , Collas DM , Ding YY , et al.   Oxybutynin with bladder retraining for detrusor instability in elderly people (a randomized controlled trial) . Age Ageing . 1995;24:287–291
  29. Zinner N , Gittelman M , Harris R , et al.   Trospium chloride improves overactive bladder symptoms (a multicenter phase III trial) . J Urol . 2004;171:2311–2315
  30. Abrams P , Larsson G , Chapple C , et al.   Factors involved in the success of antimuscarinic treatment . BJU Int . 1999;83(suppl2):42–47
  31. Burgio KL , Locher JL , Goode PS , et al.   Behavioral vs drug treatment for urge urinary incontinence in older women (a randomized controlled trial) . JAMA . 1998;280:1995–2000
  32. Derogatis LR , Rickels K , Rock AF . The SCL-90 and the MMPI (a step in the validation of a new self-report scale) . Br J Psychiatry . 1976;128:280–289
  33. Barkin J , Corcos J , Radomski S , et al.   A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence . Clin Ther . 2004;26:1026–1036
  34. Davila GW , Daugherty CA , Sanders SW . A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence . J Urol . 2001;166:140–145
  35. Halaska M , Ralph G , Wiedemann A , et al.   Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability . World J Urol . 2003;20:392–399
  36. Malone-Lee J , Shaffu B , Anand C , et al.   Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial . J Urol . 2001;165:1452–1456
  37. Abrams P , Freeman R , Anderstrom C , et al.   Tolterodine, a new antimuscarinic agent (as effective but better tolerated than oxybutynin in patients with an overactive bladder) . Br J Urol . 1998;81:801–810
  38. Chapple CR , Arano P , Bosch JL , et al.   Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study . BJU Int . 2004;93:71–77
  39. Dmochowski RR , Sand PK , Zinner NR , et al.   Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence . Urology . 2003;62:237–242
  40. Homma Y , Paick JS , Lee JG , et al.   Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder (a randomized, placebo-controlled trial) . BJU Int . 2003;92:741–747
  41. Lee JG , Hong JY , Choo MS , et al.   Tolterodine (as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder) . Int J Urol . 2002;9:247–252
  42. Leung HY , Yip SK , Cheon C , et al.   A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder . BJU Int . 2002;90:375–380
  43. Madersbacher H , Halaska M , Voigt R , et al.   A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence . BJU Int . 1999;84:646–651
  44. Thuroff JW , Bunke B , Ebner A , et al.   Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity (oxybutynin versus propantheline versus placebo) . J Urol . 1991;145:813–816 discussion 816–817
  45. Kelleher CJ , Cardozo LD , Khullar V , et al.   A new questionnaire to assess the quality of life of urinary incontinent women . Br J Obstet Gynaecol . 1997;104:1374–1379
  46. Michel MC , Oelke M , Goepel M , et al.   What determines patient satisfaction in the treatment of overactive bladder? . 2005; Presented at the 35th Annual Meeting of the International Continence Society; August 28 to September 2, Montreal, Quebec, Canada.

PII: S0090-4295(06)00772-2

doi: 10.1016/j.urology.2006.05.044

Urology
Volume 68, Issue 2, Supplement , Pages 17-28 , August 2006

Article Tools